Seaport Therapeutics, Inc. (SPTX) Key Metrics
SPTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $954.4M
- Enterprise value
- $871.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
SPTX key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSPTX returns How much profit the business earns on the capital it uses.
SPTX per-share figures Results divided by the shares outstanding at year-end.
SPTX financial health Debt, liquidity and how easily interest is covered.
SPTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SPTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SPTX key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.00 | $0.00 |
| Earnings per share | −$1.94 | −$0.88 |
| Operating cash flow per share | −$2.02 | −$0.56 |
| Free cash flow per share | −$2.03 | −$0.56 |
| Cash per share | $5.59 | $5.83 |
| Book value per share | −$2.39 | −$0.47 |
| Tangible book value per share | −$2.39 | −$0.47 |
| Capex per share | $0.01 | $0.00 |
| Debt per share | $0.13 | — |
| Shares outstanding | 38.6M | 53.0M |
| Change in shares outstanding | −27.1% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −26.5% | −14.8% |
| Return on tangible assets | −30.1% | −14.8% |
| Financial health | ||
| Total debt | $5.1M | — |
| Cash & short-term investments | $216.0M | $309.1M |
| Net debt | −$210.9M | −$309.1M |
| Debt / assets | 0.02 | — |
| Current ratio | 17.46 | 27.82 |
| Quick ratio | 17.46 | 27.82 |
| Working capital | $210.4M | $299.0M |
| Invested capital | −$303.4M | −$333.9M |
| Tangible asset value | −$92.5M | −$24.8M |
| Net current asset value | −$118.3M | −$30.5M |
| Graham net-net per share | −$3.19 | −$0.59 |
| Capital allocation | ||
| Capex / depreciation | 0.25 | 0.53 |
| Efficiency | ||
| Receivables turnover | 0.00 | — |
| Asset turnover | 0.00 | 0.00 |
| Average receivables | $3.0M | — |
| Average payables | $3.4M | $4.7M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from SPTX's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SPTX valuation and financial ratios
It ended the year with $5.1 million of debt and $216.0 million in cash and short-term investments, a net cash position of $210.9 million.
See the SPTX income statement, the SPTX chart for price history, or the SPTX stock overview for the latest quote and news.
SPTX key metrics FAQ
How much debt does Seaport Therapeutics have?
Seaport Therapeutics had total debt of $5.1 million at the end of fiscal 2025 and more cash than debt.
What is Seaport Therapeutics's current ratio?
Seaport Therapeutics's current ratio was 17.46 at the end of fiscal 2025: current assets were 17.46 times current liabilities.